Search for: "Washington v. Texas"
Results 1121 - 1140
of 3,035
Sorted by Relevance
|
Sort by Date
5 Mar 2008, 11:32 am
Deutsche Telekom AG - Washington, D.C. attorney Brian Wm. [read post]
26 May 2011, 3:04 pm
David Benowitz is a criminal defense lawyer in Washington DC and founding partner of Price Benowtiz LLP. [read post]
7 Nov 2009, 5:20 pm
City of Tenaha Deputy City Marshal Barry Washington et. al., U.S. [read post]
4 Jan 2012, 8:45 am
Arizona v. [read post]
27 Nov 2012, 2:03 am
Texas, 128 S. [read post]
2 Apr 2020, 3:47 am
At The George Washington Law Review’s On the Docket blog, Laird Kirkpatrick looks at Kahler v. [read post]
25 Apr 2012, 9:50 am
See, e.g., Furst v. [read post]
16 Mar 2012, 7:20 am
Hobbs and Miller v. [read post]
7 Jan 2015, 10:52 am
Fox v. [read post]
28 Jun 2012, 7:39 am
David Doniger, Policy Director, Climate and Clean Air Program, Washington, D.C. [read post]
15 Jul 2022, 5:00 am
In overturning Roe v. [read post]
1 Jun 2017, 4:23 am
” Additional coverage comes from Robert Barnes in The Washington Post. [read post]
19 Apr 2017, 2:30 pm
In Buck v. [read post]
23 Jun 2015, 7:31 am
At the George Washington Law Review’s On the Docket, Joan Meier discusses Ohio v. [read post]
15 Mar 2022, 9:47 am
Texas, so that it could be argued during the April session (on April 26) and decided during the current term. [read post]
5 Oct 2021, 12:33 pm
Washington. [read post]
17 Nov 2008, 8:57 pm
Retrial Date Set in RIAA v. [read post]
10 Dec 2019, 11:10 am
Texas, 18-9674Issue: Whether the standard for assessing ineffective assistance of counsel claims, announced in Strickland v. [read post]
9 Mar 2009, 6:54 am
In an op-ed for the Washington Times (3/9) Jim Copland, director of the Center for Legal Policy and Paul Howard, director of the Center for Medical Progress at the Manhattan Institute for Policy Research, write, "Pharmaceutical manufacturers in America now face a...hazardous path...after the Supreme Court ruled yesterday in Wyeth v. [read post]
9 Mar 2009, 6:54 am
In an op-ed for the Washington Times (3/9) Jim Copland, director of the Center for Legal Policy and Paul Howard, director of the Center for Medical Progress at the Manhattan Institute for Policy Research, write, "Pharmaceutical manufacturers in America now face a...hazardous path...after the Supreme Court ruled yesterday in Wyeth v. [read post]
